TTD | Drug: D0I0UE

Drug General Information
Drug ID	D0I0UE
Former ID	DNC000875
Drug Name	Lexipafant
Drug Type	Small molecular drug
Indication	Nerve injury [ICD10:T14.4]		Phase 2	[533596]
Structure		Download 2D MOL 3D MOL
Formula	C23H30N4O4S
Canonical SMILES	CCOC(=O)C(CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2<br />C=CN=C3)C
InChI	1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1
InChIKey	AQRXDPFOYJSPMP-QFIPXVFZSA-N
CAS Number	CAS 139133-26-9
PubChem Compound ID	9804204
PubChem Substance ID	14760290, 14760291, 24112430, 44840201, 47206548, 52899980, 57373383, 103319456, 103978934, 127445498, 134223779, 134339763, 134340179, 144231905, 198952538, 226553381
Target and Pathway
Target(s)	Platelet-activating factor receptor	Target Info	Modulator
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Staphylococcus aureus infection
NetPath Pathway	IL5 Signaling Pathway
NetPath Pathway	Leptin Signaling Pathway
Reactome	Class A/1 (Rhodopsin-like receptors)
	G alpha (q) signalling events
	Interferon gamma signaling
WikiPathways	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Small Ligand GPCRs
	Interferon gamma signaling
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 533596	Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 1995 Oct;82(10):1414-20.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information